RareResearch.AI
← Back to atlas

A569V

Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorial
AlanineValine at position 569 · TM8 (563-583), helical transmembrane · WFS1 (Wolframin)

Alanine → Valine at position 569 inside TM8. ClinVar Conflicting including Wolfram-like + Cataract 41 + DFNA6. AlphaMissense 0.481 (below threshold), ΔΔG +0.02. AM under-call.

Interactive 3D Structure

Wild-type reference
Wild-type A569 — hydrogen bond to L565
Fullscreen ↗
DynaMut2 mutant · A569V
Mutant V569 — energy-minimized; 1 new contact formed
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost1 gained10 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondL565L565Preserved
Hydrogen bondI572I572Preserved
Hydrogen bondL573L573Preserved
Polar contactL565L565Preserved
Polar contactI572I572Preserved
Polar contactL573L573Preserved
CarbonylI572I572Preserved
Van der WaalsL565L565Preserved
Van der WaalsI572I572Preserved
HydrophobicL565L565Preserved
HydrophobicL573Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.02kcal/mol
Stabilising — mild
AlphaMissense
0.481
Amb
AlphaFold pLDDT
73
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Reduced confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsWolfram-like syndrome; Cataract 41; Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)
InheritanceMulti-phenotype AD.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0076%
cDNA changec.1706C>T
ClinVar accessionVCV000504710
Last evaluated2025/12/24 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for Wolfram-like syndrome (autosomal dominant, OMIM 614296); Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1; Wolfram syndrome 1
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0076% · 123 / 1,613,402 alleles
Homozygotes
0
Highest-frequency population
African / African American · AF 0.140%

Highest in African / African American: AF 0.140% (105 of 75,072 alleles), 18.3x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
African / African American0.140%105 / 75,0720~1 in 360
Remaining individuals0.014%9 / 62,4860~1 in 3470
Admixed American0.0033%2 / 60,0300~1 in 15010
South Asian0.0033%3 / 91,0660~1 in 15180
European (non-Finnish)0.00034%4 / 1,179,9300~1 in 147490

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 569 in TM8. Neighbors: PHE568 (2.5 Å), LEU570 (2.5 Å), LEU565 (3.3 Å), ILE572 (4.2 Å). Hydrophobic TM environment.

A569V is a conservative volume increase. ΔΔG essentially neutral. AM 0.481 below threshold — under-call. Multi-phenotype (Wolfram-like + Cataract + DFNA6) confirms clinical pathogenicity.

Amino-acid chemistry
Alanine (A) → Valine (V) — small replaced by branched aliphatic.
Position in the protein
TM8 (residues 563–583) · position 569 mid-helix (pLDDT 73).

Druggability Assessment

Category 4 — Stable Fold, Function Disrupted (AM under-call). ΔΔG ≈ 0. AlphaMissense 0.481 below threshold but three documented phenotypes confirm pathogenicity.

Mechanism: subtle volume mismatch in TM8 hydrophobic packing. Therapeutic: TM8 site-directed.

Why this matters

A569V is the first TM8 variant at full v3 depth in the Atlas — new helix target identified.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A569V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A569V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Transmembrane563583 · Helical